



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification 6 :</b> <b>C12N 15/11, C07K 14/705, 14/47, A61K 39/00, C07K 16/30, A61K 51/08, G01N 33/68</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 98/02538</b> <b>(43) International Publication Date:</b> 22 January 1998 (22.01.98)
<b>(21) International Application Number:</b> PCT/EP97/03712 <b>(22) International Filing Date:</b> 8 July 1997 (08.07.97)  <b>(30) Priority Data:</b> 96201945.1 11 July 1996 (11.07.96) EP <b>(34) Countries for which the regional or international application was filed:</b> NL et al.  <b>(71) Applicant (for all designated States except US):</b> AKZO NOBEL N.V. [NL/NL]; Velperweg 76, NL-6824 BM Arnhem (NL).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> FIGDOR, Carl, Gustav [NL/NL]; Westwal 54, NL-5211 DD 's Hertogenbosch (NL). ADEMA, Gosse, Jan [NL/NL]; Haydnstraat 53, NL-6561 ED Groesbeek (NL).  <b>(74) Agent:</b> VAN GENT, Marieke; P.O. Box 20, NL-5340 BH Oss (NL).	<b>(81) Designated States:</b> AU, CA, JP, KR, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
<b>(54) Title:</b> MELANOMA ASSOCIATED PEPTIDE ANALOGUES AND VACCINES AGAINST MELANOMA  <b>(57) Abstract</b>  The present invention is concerned with cancer treatment and diagnosis, especially with melanoma associated peptide analogues with improved immunogenicity, epitopes thereof, vaccines against melanoma, tumour infiltrating T lymphocytes recognizing the antigen and diagnostics for the detection of melanoma and for the monitoring of vaccination. The peptides according to the invention can be exploited to elicit native epitope-reactive CTL. Usage of said peptides with improved immunogenicity may contribute to the development of CTL-epitope based vaccines in viral disease and cancer.		